Library
Comprehensive evaluation of microneedle-based intradermal adalimumab delivery versus subcutaneous administration: results of a randomized controlled trial.
5 January 2021. doid: 10.1111/bcp.14729
Jacobse J, Ten Voorde W, Tandon A, Romeijn SG, Grievink HW, van der Maaden K, van Esdonk MJ, Moes DJAR, Loeff F, Bloem K, de Vries A, Rispens T, Wolbink G, de Kam M, Ziagkos D, Moerland M, Jiskoot W, Bouwstra J, Burggraaf J, Schrier L, Rissmann R, Ten Cate R
View publicationTo evaluate feasibility of intradermal (i.d.) adalimumab administration using hollow microneedles, and to compare a single i.d. dose of adalimumab using a hollow microneedle with a single subcutaneous (s.c.) dose using a conventional needle.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
